TaiMed Biologics Inc. announced that the last patient has been successfully enrolled and dosed in a phase 2a clinical study evaluating the bi-monthly injection of the TMB-365 and TMB-380 combination for HIV therapy. This study aims to gather information regarding the efficacy, safety, and pharmacokinetics of the dual antibody combination for maintenance therapy. Such data will serve as a crucial reference for designing future clinical trials.

The target patient group for this study comprises HIV patients who have already achieved viral load suppression through first or second-line therapies and have transitioned to TMB-365/380 combination therapy without the concurrent use of other HIV drugs. Both TMB-365 and TMB-380 are monoclonal antibodies designed to provide long-lasting effects in the treatment of HIV patients. Should the trial proceed according to the plan, preliminary results are expected to be available by the end of 2024 to the early of 2025.